DEFA14A ·Filed May 14, 2026
ED

EDAP

EDAP TMS SA
BEARISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0001104659-26-060707
Proxy solicitation materials
Actionable Insight ▼ Bearish

The filing confirms deteriorating fundamentals and heightened liquidity risk. Expect potential dilutive financing or restructuring announcements. Monitor for drawdown of the remaining €12M EIB tranche and any cost-cutting measures. The annual meeting on June 26, 2026 may include votes on capital authorizations.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
EDAP ▲ +15.50% at T+20d
SHORT call ✗ call lost -15.50% · α vs SPY -16.35% · entry $4.13 → $4.77
Next anchor: T+60d due 8w ago
Latest observation: T+33 -37.66% FF3 residual α
Entry anchored
May 14, 2026
via day open
T+1d
+1.57%
call -1.57% · α -2.80%
$4.20
settled 5mo ago
T+5d
+4.84%
call -4.84% · α -5.56%
$4.33
settled 5mo ago
T+20d
+15.50%
call -15.50% · α -16.35%
$4.77
settled 4mo ago
T+60d
—
call — · α —
—
due 8w ago

Price Chart

Loading chart...

Executive Summary

EDAP TMS SA filed its management report for the 2025 fiscal year ahead of the June 26, 2026 annual general meeting. Consolidated revenue declined 2.7% to €62.4M, while net loss widened to €25.9M from €19.0M, and cash decreased by €9M to €17.4M. The company explicitly warns it needs additional capital and faces going-concern uncertainty.

Key Facts

  • FY2025 consolidated revenue €62.4M vs €64.1M in 2024 (down ~2.7%)
  • Consolidated net loss widened to €25.9M from €19.0M (36% increase)
  • Operating loss increased to €21.9M from €20.5M
  • Cash and equivalents fell €9M to €17.4M as of Dec 31, 2025
  • Company states it will need significant additional funds and may be unable to continue as a going concern

Financial Impact

Net loss widened by €6.9M YoY; cash burn of €9M; revenue decline of €1.7M

revenuenet incomecashoperating income

Risk Factors

  • Dilutive equity or debt financing likely needed within 12 months
  • Going-concern qualification in future filings if cash runway insufficient
  • Further share price decline on continued losses and no near-term profitability path

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-060707
Document: 0001104659-26-060707-index-headers.html0001104659-26-060707
Document: 0001104659-26-060707-index.html0001104659-26-060707
Document: 0001104659-26-060707.txt0001104659-26-060707
12 reports for EDAP
Performance horizon
Filters
Rows
Reports for EDAP — sortable, filterable
TypeNow
Aug 17, 2026
6w ago
Insider Cluster
MIXED ★ 5/10
—awaiting T+20——
May 29, 2026
18w ago
8-K
NEUTRAL ★ 4/10
$4.32 $5.10▲ +18.06%▲ +19.85%—
May 14, 2026
20w ago
DEFA14A
BEARISH ★ 6/10
$4.13 $4.77▼ −15.50%▼ −16.35%—
May 14, 2026
20w ago
DEFA14A
NEUTRAL ★ 3/10
$4.13 $4.77▲ +15.50%▲ +16.35%—
May 14, 2026
20w ago
Press Release
NEUTRAL ★ 3/10
$4.13 $4.77▲ +15.50%▲ +16.35%—
May 7, 2026
21w ago
8-K
MIXED ★ 6/10
$4.16 $4.69▲ +12.74%▲ +9.60%—
Apr 16, 2026
24w ago
Press Release
NEUTRAL ★ 3/10
$3.59 $4.16▲ +15.88%▲ +10.06%—
Apr 1, 2026
26w ago
EFFECT
NEUTRAL ★ 4/10
$3.53 $3.31▼ −6.23%▼ −15.95%—
Mar 27, 2026
27w ago
S-3/A
NEUTRAL ★ 4/10
$3.73 $3.22▼ −13.67%▼ −26.41%—
Mar 25, 2026
27w ago
S-3
NEUTRAL ★ 5/10
$3.77 $3.22▼ −14.59%▼ −25.25%—
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (37h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access